ReportWire

Tag: Wegovy

  • Wegovy injections vs. pills: Doctors explain the differences

    [ad_1]

    Wegovy injections vs. pills: Doctors explain the differences

    When it comes to GLP-1 pills vs. injections, doctors share which form may be best for you.

    Updated: 3:01 PM PST Jan 15, 2026

    Editorial Standards

    GLP-1 (glucagon-like peptide-1 receptor agonists) like Ozempic and Wegovy continue to make headlines as more research points to the benefits of taking these medications. Traditionally, patients administer these via injection, but now, one medication in particular is available to take in pill form. So, which works best: Wegovy injection vs. pill? And is the answer the same for all GLP-1s?First, GLP-1s are a class of drugs that mimic the GLP-1 hormone that’s naturally released in your GI tract when you eat, explains Mir Ali, M.D., medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA. These medications help to moderate blood sugar levels, reduce feelings of hunger in the brain, and delay emptying in the stomach, making you feel fuller, longer. As a result, a side effect is weight loss. There are some buzzy GLP-1 medications that have become household names, like Wegovy and Ozempic, but there are also other options you may not have heard about.Ultimately, the best GLP-1 medication is one that you and your healthcare provider agree will best serve your needs. But learning more about the medication you intend to use can’t hurt. Here, find the major differences between GLP-1 injections and pills.There are a lot of medications that fall into the GLP-1 class, including injectable drugs and pills. Some popular ones include Ozempic, Rybelsus, and Wegovy.It’s worth noting that Wegovy (the main active ingredient of which is semaglutide) is the only GLP-1 pill that’s approved for weight loss by the U.S. Food and Drug Administration (FDA). While Rybelsus is sometimes used off-label for weight loss, it’s technically FDA-approved for blood sugar management in people with type 2 diabetes (the same goes for Ozempic). So, keep in mind that the information ahead speaks primarily to Wegovy.Wegovy injection vs. pill: How does each work? GLP-1 injectable medications are usually injected into the belly. “GLP-1 injections deliver the medication into the subcutaneous fat, where it is slowly absorbed,” explains Christoph Buettner, M.D., Ph.D., chief of the division of endocrinology at Rutgers Robert Wood Johnson Medical School. “These drugs have a long half-life, about five to seven days, which is why they only need to be taken once a week.”After they’re injected, the medication steadily enters the bloodstream and activates the GLP-1 receptor, Dr. Buettner explains. Once it’s in your body, the medication signals to your brain to take in less food, says Martin Binks, Ph.D., professor and chair of the Department of Nutrition and Food Studies at George Mason University College of Public Health. “They also help delay stomach emptying, which ultimately improves satiety and reduces hunger,” he says. “The combined influences of these medicines regulate metabolism and appetite.”The GLP-1 pills work similarly, but these contain a higher dose of medication to compensate for absorption into the digestive tract, Dr. Binks says. (The injectable medications have lower doses of medication because they’re slowly released into the bloodstream and bypass the gastrointestinal tract, Dr. Ali explains.)These medications are taken by mouth once a day. They usually need to be taken on an empty stomach, and you can’t eat or take most other medications for up to an hour afterward, Dr. Buettner points out. “These requirements can be inconvenient for many patients,” he says.Which is most effective for weight loss?It depends. There have been a few clinical trials on the impact of GLP-1 injectable medications on weight loss with different results. However, People usually lose about 15% of their body weight while using semaglutide medications like Wegovy.Meanwhile, during clinical trials for the Wegovy oral route, people who took the pill lost about 16.6% of their body weight. (That’s compared to 3% weight loss achieved by people who used a placebo.)While Rybelsus isn’t FDA-approved for weight loss, people typically lose around eight pounds while taking this medication.Which works best?There are a few things to consider. “Both injectables and pill forms can be helpful,” says Dina Hagigeorges, PA.-C., a physician assistant who specializes in weight and wellness at Tufts Medicine Weight + Wellness – Stoneham. “Unfortunately, cost and insurance coverage are a huge deciding factor, as not all insurance plans cover these medications for people.” When paid for out of pocket, injectable GLP-1 medications are usually much more expensive than their oral counterparts.There’s a larger body of research to support injectable medications for weight loss, although the Wegovy pill shows promise, Dr. Ali says. “If someone can tolerate injections, it’s usually the better way to go—they’re taken less frequently,” he says. But these medications aren’t a good fit for people who are scared of needles, and they have to be refrigerated, Dr. Ali points out.“The pills are a good option for people who don’t like injections, and you can easily take them with you when you travel,” Dr. Ali says. “But they have to be taken daily, which is not for everyone.”Side effectsThe side effects are similar for both medications, Dr. Buettner says.These side effects may include:NauseaVomitingDiarrheaConstipationUpset Stomach “The most important thing is choosing a medication that you can use consistently and that aligns with your personal priorities—whether that’s maximum weight loss, convenience, avoiding injections, or simplifying your routine,” he says. “Many patients try one form first and later switch based on their experience.”So, talk to your healthcare provider and keep the line of conversation open. You may find one form of GLP-1 feels like a more natural fit over another.

    GLP-1 (glucagon-like peptide-1 receptor agonists) like Ozempic and Wegovy continue to make headlines as more research points to the benefits of taking these medications. Traditionally, patients administer these via injection, but now, one medication in particular is available to take in pill form. So, which works best: Wegovy injection vs. pill? And is the answer the same for all GLP-1s?

    First, GLP-1s are a class of drugs that mimic the GLP-1 hormone that’s naturally released in your GI tract when you eat, explains Mir Ali, M.D., medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA. These medications help to moderate blood sugar levels, reduce feelings of hunger in the brain, and delay emptying in the stomach, making you feel fuller, longer. As a result, a side effect is weight loss.

    There are some buzzy GLP-1 medications that have become household names, like Wegovy and Ozempic, but there are also other options you may not have heard about.

    Ultimately, the best GLP-1 medication is one that you and your healthcare provider agree will best serve your needs. But learning more about the medication you intend to use can’t hurt. Here, find the major differences between GLP-1 injections and pills.

    There are a lot of medications that fall into the GLP-1 class, including injectable drugs and pills. Some popular ones include Ozempic, Rybelsus, and Wegovy.

    It’s worth noting that Wegovy (the main active ingredient of which is semaglutide) is the only GLP-1 pill that’s approved for weight loss by the U.S. Food and Drug Administration (FDA). While Rybelsus is sometimes used off-label for weight loss, it’s technically FDA-approved for blood sugar management in people with type 2 diabetes (the same goes for Ozempic). So, keep in mind that the information ahead speaks primarily to Wegovy.

    Wegovy injection vs. pill: How does each work?

    GLP-1 injectable medications are usually injected into the belly. “GLP-1 injections deliver the medication into the subcutaneous fat, where it is slowly absorbed,” explains Christoph Buettner, M.D., Ph.D., chief of the division of endocrinology at Rutgers Robert Wood Johnson Medical School. “These drugs have a long half-life, about five to seven days, which is why they only need to be taken once a week.”

    After they’re injected, the medication steadily enters the bloodstream and activates the GLP-1 receptor, Dr. Buettner explains. Once it’s in your body, the medication signals to your brain to take in less food, says Martin Binks, Ph.D., professor and chair of the Department of Nutrition and Food Studies at George Mason University College of Public Health. “They also help delay stomach emptying, which ultimately improves satiety and reduces hunger,” he says. “The combined influences of these medicines regulate metabolism and appetite.”

    The GLP-1 pills work similarly, but these contain a higher dose of medication to compensate for absorption into the digestive tract, Dr. Binks says. (The injectable medications have lower doses of medication because they’re slowly released into the bloodstream and bypass the gastrointestinal tract, Dr. Ali explains.)

    These medications are taken by mouth once a day. They usually need to be taken on an empty stomach, and you can’t eat or take most other medications for up to an hour afterward, Dr. Buettner points out. “These requirements can be inconvenient for many patients,” he says.

    Which is most effective for weight loss?

    It depends. There have been a few clinical trials on the impact of GLP-1 injectable medications on weight loss with different results. However, People usually lose about 15% of their body weight while using semaglutide medications like Wegovy.

    Meanwhile, during clinical trials for the Wegovy oral route, people who took the pill lost about 16.6% of their body weight. (That’s compared to 3% weight loss achieved by people who used a placebo.)

    While Rybelsus isn’t FDA-approved for weight loss, people typically lose around eight pounds while taking this medication.

    Which works best?

    There are a few things to consider. “Both injectables and pill forms can be helpful,” says Dina Hagigeorges, PA.-C., a physician assistant who specializes in weight and wellness at Tufts Medicine Weight + Wellness – Stoneham. “Unfortunately, cost and insurance coverage are a huge deciding factor, as not all insurance plans cover these medications for people.” When paid for out of pocket, injectable GLP-1 medications are usually much more expensive than their oral counterparts.

    There’s a larger body of research to support injectable medications for weight loss, although the Wegovy pill shows promise, Dr. Ali says. “If someone can tolerate injections, it’s usually the better way to go—they’re taken less frequently,” he says. But these medications aren’t a good fit for people who are scared of needles, and they have to be refrigerated, Dr. Ali points out.

    “The pills are a good option for people who don’t like injections, and you can easily take them with you when you travel,” Dr. Ali says. “But they have to be taken daily, which is not for everyone.”

    Side effects

    The side effects are similar for both medications, Dr. Buettner says.

    These side effects may include:

    • Nausea
    • Vomiting
    • Diarrhea
    • Constipation
    • Upset Stomach

    “The most important thing is choosing a medication that you can use consistently and that aligns with your personal priorities—whether that’s maximum weight loss, convenience, avoiding injections, or simplifying your routine,” he says. “Many patients try one form first and later switch based on their experience.”

    So, talk to your healthcare provider and keep the line of conversation open. You may find one form of GLP-1 feels like a more natural fit over another.

    [ad_2]

    Source link

  • Wegovy is now available as a pill. Here’s what you need to know

    [ad_1]

    (CNN) — Americans seeking to lose weight now have a new option – taking Wegovy as a daily pill, rather than a weekly injection.

    Patients with a prescription could obtain the starter 1.5 mg dose of the tablet as of Monday, with the higher doses becoming available by the end of the week, according to manufacturer Novo Nordisk.

    Being able to address obesity with a GLP-1 pill is a significant advance in weight management. Eli Lilly is expected to receive US Food and Drug Administration approval for its oral medication, which is called orforglipron until it receives a brand name, by summer.

    But the arrival of an oral option has also sparked a multitude of questions. Here’s what we know:

    Where can I get the Wegovy pill?

    The tablet form of Wegovy can be found at pharmacies, including CVS and Costco, certain telehealth providers, such as Ro and LifeMD and Weight Watchers, NovoCare Pharmacy, GoodRx and other locations.

    Will it be hard to find?

    While overwhelming demand led to initial shortages of the GLP-1 injections, Novo Nordisk said it is confident that it can meet the demand for the Wegovy tablet.

    The Danish drug maker noted that it has invested in its manufacturing capabilities for several years. The Wegovy pill is produced entirely in its North Carolina facilities.

    How much will the pill cost?

    The 1.5 mg starter dose of the pill costs $149 a month for patients who pay cash, as part of a recent deal Novo Nordisk made with the Trump administration. The 4 mg dose costs the same amount until April 15, after which the price will increase to $199.

    However, the 9 mg and 25 mg doses cost $299 a month.

    That compares to a $349 monthly price tag for the injectable version for self-pay consumers, though new patients can receive two months of the lowest two doses for $199 each until March.

    Patients whose insurance plans cover the drug for obesity could pay as little as $25 a month for the pill or injection under a savings program offered by Novo Nordisk.

    How is the pill different from the injection?

    The pill uses the same active ingredient, semaglutide, as the injection. They’re approved by the US Food and Drug Administration for the same groups of people: those with obesity, typically defined as having a body mass index of 30 or higher, and those with overweight, or a BMI of 27 or more along with a weight-related health issue such as high blood pressure.

    The main difference between the two is how you take them – as a daily pill versus a weekly shot. The pill also must be taken on an empty stomach, with a small amount of water and no other food, drink or medicines for at least 30 minutes.

    The medicine won’t be effective if patients don’t wait 30 minutes to give the tablet time to absorb, according to Novo Nordisk.

    How much weight could I lose?

    The Wegovy tablet and injection resulted in similar weight loss in clinical trials.

    The pill showed average weight loss of 14% over 64 weeks, compared with 2% for a placebo. The injection showed weight loss of 15% in its key trial, versus 2% for placebo.

    Eli Lilly’s orforglipron showed 11% weight loss over 72 weeks on its highest dose, compared with 2% for the placebo group. Zepbound, Eli Lilly’s injectable weight loss drug, showed weight loss of 21% on its highest dose, compared with 3% for those on a placebo.

    What are the side effects of the Wegovy pill?

    Like all medicines in the class known as GLP-1s, the Wegovy pill is also associated with side effects such as nausea, vomiting, constipation and diarrhea. The pill and injection had similar tolerability in clinical trials.

    Should I consider switching from the injection to the pill?

    That depends on your specific circumstances, doctors say. If you’re someone who’d prefer a daily pill to a weekly shot, and can deal with delaying food, drink and other medications for 30 minutes after taking the Wegovy pill, it might be the right choice. Others may prefer the simplicity of a weekly injection, if they don’t mind needles.

    Dr. Jorge Moreno, an obesity specialist with Yale Medicine, said a switch to the pill may be a consideration for people who’ve experienced more tolerability issues with the injections.

    “If patients have not tolerated the injection or are having a tough time going up on the dose, they may opt to switch to the Wegovy pill,” Moreno told CNN.

    Dr. Judith Korner, an endocrinologist and director of the Metabolic and Weight Control Center at Columbia University Vagelos College of Physicians and Surgeons, pointed out that the weekly injections might be “a bit longer-lasting,” and so any uncomfortable side effects patients experience “may last longer than if you take a pill” as well, where “if you really don’t like the way you feel you don’t take it the next day.”

    If you miss a dose of the pill, that dose should be skipped, and the next dose should be taken the following day.

    Both doctors emphasized that cost also plays a large role in decision-making.

    “Insurance coverage is still hard to predict at this point,” Moreno said. “I am hopeful with lower costs for the Wegovy pill, more insurances will opt to cover it.”

    [ad_2]

    Tami Luhby, Meg Tirrell and CNN

    Source link

  • Novo Nordisk debuts Wegovy weight-loss pill in the U.S.

    [ad_1]


    A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving Americans access to an oral medication to treat obesity.

    The starting dose of the daily Wegovy pill, at 1.5 milligrams, is now available for $149 per month for self-paying patients, Novo Nordisk announced on Monday. A 4 mg dose of the medication is available for the same price through April 15, after which the cost will rise to $199.

    Ed Cinca, senior vice president of marketing and patient solutions at Novo Nordisk, said in a statement that the new drug represents a “significant innovation,” describing it as the “first and only” GLP-1 pill for weight loss. 

    The Food and Drug Administration (FDA) approved the pill version of Wegovy in December. Competitor Eli Lilly’s obesity pill, orforglipron, is still being reviewed by the FDA.

    The Novo Nordisk pill contains 25 milligrams of semaglutide, the same ingredient in injectables Wegovy and Ozempic. It also has similar side effects as the injectable version of the medication, including nausea and diarrhea, according to Novo Nordisk. 

    The new Wegovy pill provides Americans an alternative, and more convenient, option than injectable treatments, which have dominated the weight-loss market since they were introduced. Roughly 1 in 8 Americans has used an injectable GLP-1 drug for weight loss or another condition, according to a recent survey from nonprofit group KFF. 

    Like the injectable version of Wegovy, the pill is intended to help patients shed body weight when coupled with diet and exercise. Novo Nordisk said that people who used the oral medication during phase 3 of clinical trials lost about 14% of their body weight, while those who stayed on the treatment lost about 17%.

    [ad_2]

    Source link

  • 12/23: CBS Evening News

    [ad_1]


    12/23: CBS Evening News – CBS News









































    Watch CBS News



    At least 2 killed in Pennsylvania nursing home explosion; California flooding threat grows as wildfire survivors face Christmas evacuation.

    [ad_2]
    Source link

  • FDA approves weight loss drug in daily pill form

    [ad_1]


    FDA approves weight loss drug in daily pill form – CBS News









































    Watch CBS News



    Regulators at the U.S. Food and Drug Administration gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication approved to treat obesity. Dr. Jon LaPook has more.

    [ad_2]
    Source link

  • GLP-1 Weight Loss Drugs Are Getting a Major Upgrade After New FDA Approval

    [ad_1]

    The U.S. Food and Drug Administration just approved the pill form of weight-loss drug Wegovy for use in the U.S. The daily oral medication, made by Novo Nordisk, is the first of its kind used to treat obesity.  

    Both Novo Nordisk’s and competitor Eli Lilly’s injectable GLP-1 drugs, Wegovy and Zepbound, have helped transform obesity treatment around the world, and for the 100 million people in the U.S. impacted by the disease, according to NPR. But Eli Lilly’s oral drug orforglipron is still awaiting approval, with a decision expected by spring. 

    The Pill Versus Injectable Drug

    All GLP-1 drugs are known to cause similar side effects, like nausea and diarrhea. Around one in eight Americans have taken the injectable kind, according to a survey from nonprofit health policy research group KFF. But for even more people in need of the medication, the shots are too expensive. 

    “There’s an entire demographic that can benefit from the pills,” Fatina Cody Stanford, an obesity expert at Massachusetts General Hospital, told NPR. “For me, it’s not just about who gets it across the finish line first. It’s about having these options available to patients.”

    While injectable GLP-1 drugs can cost over $1,000 a month, producing pills is typically much cheaper. Novo Nordisk has said customers will pay $149 per month for the Wegovy pill starting dose, with further cost information released next month. 

    “It’s all about the price,” said Angela Fitch, an obesity expert and chief medical officer at knownwell, a health care company. “Just give me a drug at $100 a month that is relatively effective.” 

    The Trial

    Chris Mertens is a pediatric lung doctor who participated in the Novo Nordisk trial starting in 2022. He told NPR he lost roughly 40 pounds using the Wegovy pill.

    [ad_2]

    Ava Levinson

    Source link

  • FDA approves Wegovy pill for weight loss

    [ad_1]

    U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.The U.S. Food and Drug Administration’s approval handed drugmaker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill. Lilly’s oral drug, orforglipron, is still under review.Both pills are GLP-1 drugs that work like widely used injectables to mimic a natural hormone that controls appetite and feelings of fullness.Video above: Doctor’s perspective on making GLP-1s more affordableIn recent years, Novo Nordisk’s injectable Wegovy and Lilly’s Zepbound have revolutionized obesity treatment globally and in the U.S., where 100 million people have the chronic disease.The Wegovy pills are expected to be available within weeks, company officials said. Availability of oral pills to treat obesity could expand the booming market for obesity treatments by broadening access and reducing costs, experts said.About 1 in 8 Americans have used injectable GLP-1 drugs, according to a survey from KFF, a nonprofit health policy research group. But many more have trouble affording the costly shots.“There’s an entire demographic that can benefit from the pills,” said Dr. Fatima Cody Stanford, a Massachusetts General Hospital obesity expert. “For me, it’s not just about who gets it across the finish line first. It’s about having these options available to patients.”The Novo Nordisk obesity pill contains 25 milligrams of semaglutide. That’s the same ingredient in injectables Wegovy and Ozempic and in Rybelsus, a lower-dose pill approved to treat diabetes in 2019.In a clinical trial, participants who took oral Wegovy lost 13.6% of their total body weight on average over about 15 months, compared with a 2.2% loss if they took a placebo, or dummy pill. That’s nearly the same as injectable Wegovy, with an average weight loss of about 15%.Chris Mertens, 35, a pediatric lung doctor in Menomonee Falls, Wisconsin, joined the Novo Nordisk trial in 2022 and lost about 40 pounds using the Wegovy pill. The daily medication worked to decrease his appetite and invasive thoughts of food, he said.“If there were days where I missed a meal, I almost didn’t realize it,” Mertens said.Participants in a clinical trial who took the highest dose of Lilly’s orforglipron lost 11.2% of their total body weight on average over nearly 17 months, compared with a 2.1% loss in those who took a placebo.Both pills resulted in less weight loss than the average achieved with Lilly’s Zepbound, or tirzepatide, which targets two gut hormones, GLP-1 and GIP, and led to a 21% average weight loss.All the GLP-1 drugs, oral or injectable, have similar side effects, including nausea and diarrhea.Both daily pills promise convenience, but the Wegovy pill must be taken with a sip of water in the morning on an empty stomach, with a 30-minute break before eating or drinking.That’s because Novo Nordisk had to design the pill in a way that prevented the drug from being broken down in the stomach before it could be absorbed by the bloodstream. The drugmaker added an ingredient that protects the medication for about 30 minutes in the gut and makes it easier to take effect.By contrast, Lilly’s orforglipron has no dosing restrictions. That drug is being considered under the FDA’s new priority voucher program aimed at cutting drug approval times. A decision is expected by spring.Producing pills is generally cheaper than making drugs delivered via injections, so the cost for the new oral medications could be lower. The Trump administration earlier this year said officials had worked with drugmakers to negotiate lower prices for the GLP-1 drugs, which can cost upwards of $1,000 a month.The company said the starting dose would be available for $149 per month from some providers. Additional information on cost will be available in January.It’s not clear whether daily pills or weekly injections will be preferred by patients. Although some patients dislike needles, others don’t seem to mind the weekly injections, obesity experts said. Mertens turned to injectable Zepbound when he regained weight after the end of the Wegovy pill clinical trial.He said he liked the discipline of the daily pill.“It was a little bit of an intentional routine and a reminder of today I’m taking this so that I know my choices are going to be affected for the day,” he said.Dr. Angela Fitch, an obesity expert and chief medical officer of knownwell, a health care company, said whatever the format, the biggest benefit will be in making weight-loss medications more widely accessible and affordable.“It’s all about the price,” she said. “Just give me a drug at $100 a month that is relatively effective.”

    U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

    The U.S. Food and Drug Administration’s approval handed drugmaker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill. Lilly’s oral drug, orforglipron, is still under review.

    Both pills are GLP-1 drugs that work like widely used injectables to mimic a natural hormone that controls appetite and feelings of fullness.

    Video above: Doctor’s perspective on making GLP-1s more affordable

    In recent years, Novo Nordisk’s injectable Wegovy and Lilly’s Zepbound have revolutionized obesity treatment globally and in the U.S., where 100 million people have the chronic disease.

    The Wegovy pills are expected to be available within weeks, company officials said. Availability of oral pills to treat obesity could expand the booming market for obesity treatments by broadening access and reducing costs, experts said.

    About 1 in 8 Americans have used injectable GLP-1 drugs, according to a survey from KFF, a nonprofit health policy research group. But many more have trouble affording the costly shots.

    “There’s an entire demographic that can benefit from the pills,” said Dr. Fatima Cody Stanford, a Massachusetts General Hospital obesity expert. “For me, it’s not just about who gets it across the finish line first. It’s about having these options available to patients.”

    The Novo Nordisk obesity pill contains 25 milligrams of semaglutide. That’s the same ingredient in injectables Wegovy and Ozempic and in Rybelsus, a lower-dose pill approved to treat diabetes in 2019.

    In a clinical trial, participants who took oral Wegovy lost 13.6% of their total body weight on average over about 15 months, compared with a 2.2% loss if they took a placebo, or dummy pill. That’s nearly the same as injectable Wegovy, with an average weight loss of about 15%.

    Chris Mertens, 35, a pediatric lung doctor in Menomonee Falls, Wisconsin, joined the Novo Nordisk trial in 2022 and lost about 40 pounds using the Wegovy pill. The daily medication worked to decrease his appetite and invasive thoughts of food, he said.

    “If there were days where I missed a meal, I almost didn’t realize it,” Mertens said.

    Participants in a clinical trial who took the highest dose of Lilly’s orforglipron lost 11.2% of their total body weight on average over nearly 17 months, compared with a 2.1% loss in those who took a placebo.

    Both pills resulted in less weight loss than the average achieved with Lilly’s Zepbound, or tirzepatide, which targets two gut hormones, GLP-1 and GIP, and led to a 21% average weight loss.

    All the GLP-1 drugs, oral or injectable, have similar side effects, including nausea and diarrhea.

    Both daily pills promise convenience, but the Wegovy pill must be taken with a sip of water in the morning on an empty stomach, with a 30-minute break before eating or drinking.

    That’s because Novo Nordisk had to design the pill in a way that prevented the drug from being broken down in the stomach before it could be absorbed by the bloodstream. The drugmaker added an ingredient that protects the medication for about 30 minutes in the gut and makes it easier to take effect.

    By contrast, Lilly’s orforglipron has no dosing restrictions. That drug is being considered under the FDA’s new priority voucher program aimed at cutting drug approval times. A decision is expected by spring.

    Producing pills is generally cheaper than making drugs delivered via injections, so the cost for the new oral medications could be lower. The Trump administration earlier this year said officials had worked with drugmakers to negotiate lower prices for the GLP-1 drugs, which can cost upwards of $1,000 a month.

    The company said the starting dose would be available for $149 per month from some providers. Additional information on cost will be available in January.

    It’s not clear whether daily pills or weekly injections will be preferred by patients. Although some patients dislike needles, others don’t seem to mind the weekly injections, obesity experts said. Mertens turned to injectable Zepbound when he regained weight after the end of the Wegovy pill clinical trial.

    He said he liked the discipline of the daily pill.

    “It was a little bit of an intentional routine and a reminder of today I’m taking this so that I know my choices are going to be affected for the day,” he said.

    Dr. Angela Fitch, an obesity expert and chief medical officer of knownwell, a health care company, said whatever the format, the biggest benefit will be in making weight-loss medications more widely accessible and affordable.

    “It’s all about the price,” she said. “Just give me a drug at $100 a month that is relatively effective.”

    [ad_2]

    Source link

  • FDA approves Wegovy pill for weight loss, the first daily oral medication of its kind

    [ad_1]

    U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

    The U.S. Food and Drug Administration’s approval handed drugmaker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill. Lilly’s oral drug, orforglipron, is still under review.

    Both pills are GLP-1 drugs that work like widely used injectables to mimic a natural hormone that controls appetite and feelings of fullness.

    In recent years, Novo Nordisk’s injectable Wegovy and Lilly’s Zepbound have revolutionized obesity treatment globally and in the U.S., where 100 million people have the chronic disease.

    The Wegovy pills are expected to be available within weeks, company officials said. Availability of oral pills to treat obesity could expand the booming market for obesity treatments by broadening access and reducing costs, experts said.

    About 1 in 8 Americans have used injectable GLP-1 drugs, according to a survey from KFF, a nonprofit health policy research group. But many more have trouble affording the costly shots.

    “There’s an entire demographic that can benefit from the pills,” said Dr. Fatima Cody Stanford, a Massachusetts General Hospital obesity expert. “For me, it’s not just about who gets it across the finish line first. It’s about having these options available to patients.”

    The Novo Nordisk obesity pill contains 25 milligrams of semaglutide. That’s the same ingredient in injectables Wegovy and Ozempic and in Rybelsus, a lower-dose pill approved to treat diabetes in 2019.

    How much weight did people lose?

    In a clinical trial, participants who took oral Wegovy lost 13.6% of their total body weight on average over about 15 months, compared with a 2.2% loss if they took a placebo, or dummy pill. That’s nearly the same as injectable Wegovy, with an average weight loss of about 15%.

    Chris Mertens, 35, a pediatric lung doctor in Menomonee Falls, Wisconsin, joined the Novo Nordisk trial in 2022 and lost about 40 pounds using the Wegovy pill. The daily medication worked to decrease his appetite and invasive thoughts of food, he said.

    “If there were days where I missed a meal, I almost didn’t realize it,” Mertens said.

    Participants in a clinical trial who took the highest dose of Lilly’s orforglipron lost 11.2% of their total body weight on average over nearly 17 months, compared with a 2.1% loss in those who took a placebo.

    Both pills resulted in less weight loss than the average achieved with Lilly’s Zepbound, or tirzepatide, which targets two gut hormones, GLP-1 and GIP, and led to a 21% average weight loss.

    All the GLP-1 drugs, oral or injectable, have similar side effects, including nausea and diarrhea.

    Both daily pills promise convenience, but the Wegovy pill must be taken with a sip of water in the morning on an empty stomach, with a 30-minute break before eating or drinking.

    That’s because Novo Nordisk had to design the pill in a way that prevented the drug from being broken down in the stomach before it could be absorbed by the bloodstream. The drugmaker added an ingredient that protects the medication for about 30 minutes in the gut and makes it easier to take effect.

    By contrast, Lilly’s orforglipron has no dosing restrictions. That drug is being considered under the FDA’s new priority voucher program aimed at cutting drug approval times. A decision is expected by spring.

    How much will the Wegovy pills cost?

    Producing pills is generally cheaper than making drugs delivered via injections, so the cost for the new oral medications could be lower. The Trump administration earlier this year said officials had worked with drugmakers to negotiate lower prices for the GLP-1 drugs, which can cost upwards of $1,000 a month.

    The company said the starting dose would be available for $149 per month from some providers. Additional information on cost will be available in January.

    It’s not clear whether daily pills or weekly injections will be preferred by patients. Although some patients dislike needles, others don’t seem to mind the weekly injections, obesity experts said. Mertens turned to injectable Zepbound when he regained weight after the end of the Wegovy pill clinical trial.

    He said he liked the discipline of the daily pill.

    “It was a little bit of an intentional routine and a reminder of today I’m taking this so that I know my choices are going to be affected for the day,” he said.

    Dr. Angela Fitch, an obesity expert and chief medical officer of knownwell, a health care company, said whatever the format, the biggest benefit will be in making weight-loss medications more widely accessible and affordable.

    “It’s all about the price,” she said. “Just give me a drug at $100 a month that is relatively effective.”

    [ad_2]

    Source link

  • Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says

    [ad_1]

    An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, Novo Nordisk said Monday.In two Phase 3 trials of more than 3,800 adults receiving standard care for Alzheimer’s, the company evaluated whether an older pill form of semaglutide worked better than a placebo. The drug was shown to be safe and led to improvements in Alzheimer’s-related biomarkers, the company said, but the treatment did not delay disease progression.Novo had long treated Alzheimer’s as a long-shot bet for the popular GLP-1 drugs. Use of these drugs for diabetes and weight loss has exploded in recent years, and they have shown benefits for a wide range of additional health conditions, such as protecting the heart and kidneys, reducing sleep apnea and potentially helping with addiction.Smaller trials and animal studies had suggested GLP-1s might help slow cognitive decline or reduce neuro-inflammation but larger trials like Novo’s were needed to confirm whether patients saw actual benefits.”Based on the significant unmet need in Alzheimer’s disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” said Martin Holst Lange, chief scientific officer and executive vice president of Research and Development at Novo Nordisk said in a statement on Monday that thanked trial participants.A one-year extension of the trials will be discontinued, Novo said. Results from the trials have not yet been peer-reviewed or published but will be presented at upcoming scientific conferences.Novo has been facing increased competition in the weight loss market and recently announced lowered prices for some cash-paying patients using Ozempic and Wegovy. Novo shares fell Monday after the Alzheimer’s trial announcement.

    An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, Novo Nordisk said Monday.

    In two Phase 3 trials of more than 3,800 adults receiving standard care for Alzheimer’s, the company evaluated whether an older pill form of semaglutide worked better than a placebo. The drug was shown to be safe and led to improvements in Alzheimer’s-related biomarkers, the company said, but the treatment did not delay disease progression.

    Novo had long treated Alzheimer’s as a long-shot bet for the popular GLP-1 drugs. Use of these drugs for diabetes and weight loss has exploded in recent years, and they have shown benefits for a wide range of additional health conditions, such as protecting the heart and kidneys, reducing sleep apnea and potentially helping with addiction.

    Smaller trials and animal studies had suggested GLP-1s might help slow cognitive decline or reduce neuro-inflammation but larger trials like Novo’s were needed to confirm whether patients saw actual benefits.

    “Based on the significant unmet need in Alzheimer’s disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” said Martin Holst Lange, chief scientific officer and executive vice president of Research and Development at Novo Nordisk said in a statement on Monday that thanked trial participants.

    A one-year extension of the trials will be discontinued, Novo said. Results from the trials have not yet been peer-reviewed or published but will be presented at upcoming scientific conferences.

    Novo has been facing increased competition in the weight loss market and recently announced lowered prices for some cash-paying patients using Ozempic and Wegovy. Novo shares fell Monday after the Alzheimer’s trial announcement.

    [ad_2]

    Source link

  • Trump Announces Sweeping Cost Cuts On Obesity Drugs – KXL

    [ad_1]

    WASHINGTON, DC – President Trump is announcing sweeping cost cuts on obesity drugs. The White House says that Eli Lilly, which makes Zepbound, and Novo Nordisk, which manufactures Wegovy, will lower the price of those injectable weight loss drugs to as little as $350 a month for starter doses. The list prices now exceed $1,000.

    Trump also says that Medicare will start covering the drugs and that if the Food and Drug Administration approves oral anti-obesity tablets, the lowest dose will cost $149 a month. In exchange, the White House has agreed to give the drugmakers a priority two-month review for certain drugs and a break on tariffs.

    All this will start in January when TrumpRX, the administration’s direct-to-consumer website, launches.

    More about:

    [ad_2]

    Tim Lantz

    Source link

  • Semaglutide Helps Your Heart Even If the Scale Doesn’t Budge, Study Shows

    [ad_1]

    The benefits of semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, aren’t just limited to treating obesity. New research shows that semaglutide can protect people’s hearts regardless of how many pounds they lose while taking it.

    Scientists examined data from a large-scale clinical trial of people with obesity and pre-existing cardiovascular disease. Compared to people on placebo, they found, those on semaglutide were less likely to develop heart attacks and other cardiovascular problems—even when people hadn’t lost much weight at all. The results indicate that semaglutide can improve heart health in more than one way, the researchers and outside experts say.

    The findings “highlight that the cardioprotective effects of semaglutide may be independent of adiposity and weight loss,” Laurence Sperling, a preventive cardiologist at Emory University not affiliated with the study, told Gizmodo.

    Good for the heart

    Semaglutide and other GLP-1 drugs have heralded a new era of obesity (and diabetes) treatment. But for a time, it was unclear if these drugs would also improve people’s cardiovascular health, and to what extent.

    Novo Nordisk (the makers of Ozempic and Wegovy) funded a large, randomized, controlled, and double-blinded study designed to answer that open question—the SELECT trial. It involved roughly 17,000 people with obesity and a history of cardiovascular disease, who were followed for up to five years. The primary results from the SELECT trial, published almost two years ago, showed that high-dose semaglutide (the version approved as Wegovy for treating obesity) reduced people’s risk of heart attacks and other major cardiovascular events by 20% during the study period. Based on these findings, the Food and Drug Administration expanded its approval of Wegovy to also cover the prevention of cardiovascular disease in high-risk groups.

    Since obesity is known to increase the risk of heart disease, it’s easy to assume that semaglutide’s heart benefits are mostly tied to helping people lose weight. But some evidence has already suggested it’s more complicated than that. In this new research, some of the researchers who conducted the SELECT trial took a closer look at their data.

    They ultimately found no clear relationship between how much weight someone had lost early into the study (20 weeks in) and their reduced risk of cardiovascular disease. The heart-protective benefits of semaglutide were also largely the same across different baseline weight groups. In other words, someone who was overweight (a body mass index between 27 and 30) at the start of the study tended to see a similar reduction in heart disease risk as compared to someone with the highest level of obesity (a BMI over 40).

    “This gives us important information that maybe we should be looking at the indication for these drugs beyond just whether your BMI is more than 27,” Howard Weintraub, preventive cardiologist and clinical director at the Center for the Prevention of Cardiovascular Disease at NYU Langone Heart, told Gizmodo. Weintraub was one of the lead researchers of the original SELECT trial but wasn’t involved in the new research.

    The study did see an association between someone’s waist circumference throughout the study and heart disease risk. The more a person’s waist shrunk, for instance, the greater reduction in risk they had. Waist circumference is another measure of excess body fat. So semaglutide’s slimming of body fat does seem to help explain why it prevents heart disease—but only partly. The researchers estimated that just a third of semaglutide’s effect on lowering cardiovascular disease could be accounted for by a trimming waistline.

    The team’s findings were published Tuesday in The Lancet.

    Beyond weight loss

    The authors say these findings could have far-reaching implications for how semaglutide and similar GLP-1 drugs should be used. If its heart benefits are largely independent of weight loss, then it wouldn’t be helpful to limit the prescribing of these drugs based solely on BMI. People taking semaglutide who lose enough weight to no longer qualify as obese might still benefit from continuing the drug for its heart-protective effects—just as those who don’t lose much weight may, too.

    It’s even possible that GLP-1 therapy could one day be reframed as a standalone treatment for heart disease, regardless of BMI. Richard Kovacs, the interim chief of cardiovascular medicine at Indiana University’s School of Medicine, who is not involved with the study, notes that these findings could shape future guidelines in how doctors manage cardiovascular disease.

    “This is a potential guideline changer because of its robust effect here. This is a well-run, large trial that we’re all familiar with. It’s an important analysis of it,” Kovacs, who is also the chief medical officer for the American College of Cardiology, told Gizmodo. At the same time, he adds, it would probably still take more data from at least one other large randomized trial for such a change to happen easily.

    One important question left to answer is exactly how these drugs can improve our heart health. The researchers argue that some of the drug’s protection likely stems from its anti-inflammatory effects, both on excess body fat and elsewhere. But the drug’s influence on blood sugar control or our blood vessels could also be playing a part.

    Yet another question is whether these heart-bolstering effects can be seen in people who aren’t overweight or obese—something that Kovacs suspects will be put to the test soon enough. And it’s still important to study whether similar benefits are apparent with other GLP-1 medications, including newer drugs that are combining GLP-1s with other compounds.

    For now, this research is continuing to demonstrate that there’s still so much left to learn about these already game-changing drugs.

    “I don’t think we know everything that the GLP-1 agonists do yet,” Weintraub said. “So doctors will need to look at this beyond the prism of a TikTok video, where kids are looking to lose a couple of pounds to look better. That may certainly happen, but I think the cosmetic issues and the role of weight loss are just a small part of it. And as a cardiologist, I’m more motivated by the sort of findings we’re seeing here in reducing cardiovascular disease.”

    [ad_2]

    Ed Cara

    Source link

  • Shot Gate? Costco Enters Weight Loss Chat With Discounted Ozempic & The Timeline Erupts (VIDEO)

    [ad_1]

    If you’ve been side-eyeing those viral weight-loss shots but couldn’t justify the price tag, Costco just might’ve changed the game. The wholesale giant is now offering Wegovy and Ozempic — yep, the same blockbuster drugs all over your timeline — at a major discount for its members. And, let’s just say…the TL is shook.

    RELATED: Serena Williams Opens Up About 31-Pound Weight Loss With Meds & Social Media Is Sounding Off (VIDEO)

    Costco’s Drug Deal Shakes Up Weight Loss Market

    According to drugmaker Novo Nordisk, Costco pharmacies are selling the medications for $499 a month for self-pay members — way less than the list price of $1,349. And, if you’ve got that Executive Membership or use a Costco Citibank Visa, you can snatch an extra 2% off. Novo Nordisk says this collab is all about access, especially as they compete with Eli Lilly’s rival meds, Zepbound and Mounjaro, while also trying to edge out those unregulated compounded versions flooding medical spas and telehealth sites.

    Social Media Split Over Costco’s Weight Loss Move

    One Instagram user @fullfigureblackbarbie said, “Now I’m going to try it

    And, Instagram user @4beautiful_mel added, “Welp looks like I’m signing up with Costco 😂”

    Instagram user @holland7367 commented, “$500 is still outrageous

    Meanwhile, Instagram user @therealdjstacks shared, “Ain’t Ozempic getting sued like crazy right now 😆”

    While Instagram user @mr.6foot9 commented, “This sh*t going to ruin life’s later on lol

    Then Instagram user @crownthyking wrote, “Imagine a lady in a apron saying you ‘want to try [a] shot’ in Costco 🤣”

    Instagram user @fantoine14 said, “Is it the Kirkland brand 😂😂😂”

    Lastly, Instagram user @ajo_mvv added, “Any employee discounts? If so, where do I apply?

    Ozempic Hype Grows As Costco Joins In

    But, make no mistake, this is still big business. Wegovy and Ozempic are FDA-approved GLP-1 injections that help curb appetite and promote weight loss. While Ozempic is officially for Type 2 diabetes, both drugs have been flying off shelves thanks to their off-label use for dropping pounds. With Costco entering the chat, folks might finally get their hands on these meds without blowing the budget — and let’s just say, the girls (and the guys) are ready to load up the cart.

    RELATED: Don’t Get It Twisted! Lizzo Addresses Ozempic Rumors & Reveals Truth Behind Her Weight Loss (VIDEO)

    What Do You Think Roomies?

    [ad_2]

    Desjah

    Source link

  • Costco is selling weight-loss drugs Ozempic, Wegovy at discounted prices

    [ad_1]

    Costco now is selling Ozempic and Wegovy at discounted prices, a move that expands access to the popular weight-loss drugs.

    Costco members with prescriptions can purchase the drugs out-of-pocket for $499 per month, a cost that is well below list prices. For members with health insurance, the price will depend on their plans. The sticker price for Ozempic is about $1,000; Wegovy costs $1,350.


    MORE: Long-term study on HPV vaccinations finds evidence of herd immunity


    Novo Nordisk, the Danish company that manufacturers Ozempic and Wegovy, already offers the drugs at $499 on its website, and also at CVS and Walmart. 

    “We want to make sure we offer the real, authentic Wegovy and Ozempic where patients seek care,” David Moore, executive vice president of Novo Nordisk’s U.S. Operations, told NBC News on Friday. “We know that Costco is a trusted brand.

    “Those patients that have coverage will receive the medicine on average for $25 a month,” Moore added. “But that doesn’t cover everyone, so we wanted to make sure there’s a self-pay option available as well.” 

    A Novo Nordisk spokesperson said Monday that Costo’s executive members and customers with a Costco Citibank Visa credit card also will receive a cash back reward and an additional 2% discount when purchasing the drugs. 

    Costco did not immediately respond to a request for comment. 

    Ozempic and Wegovy are GLP-1 drugs, a classification that also includes Zepbound, a medication made by Eli Lilly. They help people lose weight by mimicking a hormone known as glucagon-like peptide 1 that slows digestion, regulates blood sugar and signals fullness to the brain. 

    Ozempic was approved as a diabetes drug; Wegovy and Zepbound were approved to treat obesity. But they have been used off label to help people lose weight. Studies also have suggested they may have additional health benefits, including reducing risk of heart disease, dementia and addiction to alcohol or nicotine.

    The demand for the drugs has skyrocketed in recent years ago. A 2024 survey found 1 in 8 adults said they have used a GLP-1 drugs. With so many people using the drugs, insurers say they have struggled to cover the costs, because the drugs must be taken indefinitely to maintain weight loss and other health benefits. 

    The Trump administration plans to roll out a five-year, experimental program that would allow state Medicaid programs and Medicare Part D plans to cover GLP-1 agonists for weight loss. Some state Medicaid programs, including those in Pennsylvania and New Jersey, cover the drugs for obesity, and Medicare covers them for diabetes. 

    [ad_2]

    Molly McVety

    Source link

  • Costco now sells Ozempic and Wegovy at its pharmacies

    [ad_1]




































    Costco to sell weight loss drugs



    Costco now selling weight loss drugs Ozempic, Wegovy at a discount

    03:19

    Costco customers can now buy Ozempic and Wegovy at the discount chain’s drugstores.

    Novo Nordisk, the Danish pharmaceutical firm that makes the weight-loss drugs, announced Friday that Ozempic and Wegovy are available at Costco pharmacies across the U.S. A one-month supply of the drugs at the retailer will run $499, the same price they are listed for on Novo Nordisk’s direct-to-consumer website, as well as at CVS and Walmart. 

    Ozempic and Wegovy typically retail for around $1,300 and $1,600, respectively, according to GoodRx, which compares drug prices from different pharmacies.

    Costco executive members and Costco Citibank Visa card holders also receive an additional 2% discount on Ozempic and Wegovy, a Novo Nordisk  spokesperson told CBS News in an email. Members of the discount chain will still require a prescription to obtain the weight-loss drugs. 

    “Our collaboration with Costco is another step forward by Novo Nordisk in making real Wegovy® and Ozempic easier to access and afford — right where people already shop,” Dave Moore, executive vice president for Novo Nordisk’s U.S. Operations, said in a statement.

    Costco did not immediately respond to a request for comment.

    Ozempic and Wegovy are semaglutide weight-loss injection drugs that suppress users’ appetites, helping them lose weight. Ozempic is designed for adults with Type 2 diabetes and helps adults lower blood sugar. It also has been shown to reduce heart and kidney problems. 

    The U.S. Food and Drug Administration said last year that Wegovy, which unlike Ozempic has been FDA-approved for weight loss, could be used to reduce the risk of heart attacks and heart strokes in certain patients.

    [ad_2]

    Source link

  • Costco now selling weight loss drugs Ozempic, Wegovy at a discount

    [ad_1]



    Costco now selling weight loss drugs Ozempic, Wegovy at a discount – CBS News










































    Watch CBS News



    Shoppers can now find Ozempic and Wegovy at Costco. It says it is partnering with drugmaker Novo Nordisk to offer the drugs at a steep discount for members with a prescription. CBS News reporter Andres Gutierrez has more.

    [ad_2]
    Source link

  • The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research

    The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research

    [ad_1]

    The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research – CBS News


    Watch CBS News



    Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide — while adding great heft to the economy of Novo Nordisk’s home country, Denmark.

    Be the first to know

    Get browser notifications for breaking news, live events, and exclusive reporting.


    [ad_2]

    Source link

  • Don’t Look Now, But Ozempic Might Help You Quit Smoking, Too

    Don’t Look Now, But Ozempic Might Help You Quit Smoking, Too

    [ad_1]

    Semaglutide, the active ingredient in popular weight loss drugs Wegovy and Ozempic, may help people quit smoking, too. New research published Monday has found evidence that semaglutide can prevent or treat people’s nicotine dependence. More study will be needed to confirm this potential benefit, however.

    Semaglutide and other newer GLP-1 drugs have proven to be substantially more effective at helping people lose weight than diet and exercise alone. But scientists at Case Western Reserve University, led by researcher Rong Xu, have been studying the possible effects of semaglutide and similar drugs that might extend beyond treating weight loss and type 2 diabetes. Earlier this month, for instance, they published a study finding that GLP-1 drugs may be able to reduce the overall risk of obesity-related cancer in people with diabetes. Their new research, published in the Annals of Internal Medicine, looked at the connection between semaglutide use and nicotine use disorder.

    The researchers analyzed the health records of over 200,000 diabetes patients after they were newly prescribed one of several antidiabetes medications, including nearly 6,000 people who were prescribed semaglutide. They found that semaglutide users were noticeably less likely to be diagnosed with tobacco use disorder or to be given treatments for it (i.e., drugs or counseling) over the following year. This pattern held true when the researchers only looked at people with or without obesity as well.

    “While there are effective medications to support people if they wish to stop smoking, not everyone responds to them,” said Xu, a biomedical informatics professor at Case Western, in a statement from the university. “As a result of the high relapse rates, alternative medications to help people stop smoking are needed.”

    The team’s findings alone cannot prove that semaglutide and similar drugs can help treat tobacco addiction. But anecdotes and some studies (including one by the same scientists published in May) have increasingly suggested that GLP-1 drugs can temper harmful cravings caused by other vices such as alcohol and even gambling. As a result, scientists elsewhere have begun to test out semaglutide for alcohol use disorder in clinical trials (with early promising results so far)—a trend that should be followed with nicotine as well, the authors say. “These findings suggest the need for clinical trials to evaluate semaglutide’s potential for [tobacco use disorder] treatment,” they wrote in their paper.

    From potentially preventing cancer to possibly keeping our brains sharper as we reach our later years, is there anything that semaglutide can’t do?

    [ad_2]

    Ed Cara

    Source link

  • Use Of Wegovy And Other Weight-Loss Drugs Soar Among Kids And Young Adults – KXL

    Use Of Wegovy And Other Weight-Loss Drugs Soar Among Kids And Young Adults – KXL

    [ad_1]

    (Associated Press) – Use of diabetes and obesity medications such as Ozempic, Wegovy and other so-called GLP-1 drugs has soared among teens and young adults.

    New research shows that the number of 12- to 25-year-olds who used the medications climbed from about 8,700 a month in 2020 to 60,000 a month in 2023.

    Overall, in 2023, nearly 31,000 children aged 12 to 17 and more than 162,000 people aged 18 to 25 received the drugs.

    The report was published Wednesday in the journal JAMA.

    It’s the first look at the national uptake of these medications in those age groups.

    More about:

    [ad_2]

    Grant McHill

    Source link

  • Hims & Hers says it’s selling a GLP-1 weight loss drug for 85% less than Wegovy. Here’s the price.

    Hims & Hers says it’s selling a GLP-1 weight loss drug for 85% less than Wegovy. Here’s the price.

    [ad_1]

    Direct-to-consumer pharmaceutical startup Hims & Hers Health said it is selling injectable GLP-1 weight loss drugs for a fraction of the cost of brand-name competitors such as Wegovy and Ozempic. Following the announcement, shares of the telehealth company soared more than 30% Monday.

    Hims & Hers will provide patients with compounded GLP-1 drugs that start at $199 a month, or about 85% less than brand-name versions like Ozempic and Wegovy. The injectables use the same active ingredients as the branded versions, which currently are in short supply in some doses.

    Shares of Hims & Hers soared $4.21, or 29%, to $18.79 in Monday afternoon trading.

    GLP-1 drugs, which stands for glucagon-like peptide 1 agonists, help people feel fuller and less hungry, aiding their efforts to lose weight. But the brand-name versions made by a handful of pharmaceutical companies can be pricey, with Novo Nordisk’s Wegovy costing about $1,350 a month, or more than $16,00 a year, without insurance, according to GoodRx

    Hims & Hers Health’s may also beat out competitors on another key metric: availability. The startup said its GLP-1 injectable drug, which is made in partnership with a manufacturer of compounded injectable medications, will have “consistent” availability.

    The company added that it will also sell brand-name versions of GLP-1 drugs, once supply rebounds. 

    “We’ve leveraged our size and scale to secure access to one of the highest-quality supplies of compounded GLP-1 injections available today,” Hims & Hers Health CEO and co-founder Andrew Dudum said in a statement Monday. “We’re passing that access and value along to our customers, who deserve the highest standard of clinical safety and efficacy to meet their goals, and we’re doing it in a safe, affordable way that others can’t deliver.”

    Customers will need a prescription from their medical provider, based on what is “medically appropriate and necessary for each patient,” the company said. 

    The company is tapping an opportunity to profit by focusing on Americans’ desire to slim down. It already has an existing weight-loss program that is on track to bring in more than $100 million in revenue by 2025, with the program selling oral weight-loss medications for about $79 per month.

    Compounded drugs are made by pharmacists to tailor a medication to a patient or if some drugs are in short supply. To be sure, the Food and Drug Administration warns that patients should not use compounded drugs when approved drugs are available to patients.

    The agency does not review compounded GLP-1 medications for safety, and said it has received “adverse event reports” from patients who have used compounded semaglutide medications. 

    Some consumers have turned to compounded versions of the medications as demand for brand name drugs like Wegovy, Ozempic and Eli Lilly’s Mounjaro, dubbed “miracle drugs” by users who have slimmed down, soars and strains supply.

    [ad_2]

    Source link

  • Ozempic overdose? Poison control experts explain why thousands OD'd this year

    Ozempic overdose? Poison control experts explain why thousands OD'd this year

    [ad_1]

    Some of those taking Ozempic or Wegovy are learning that too much of a good thing is never good.

    Semaglutide, the medication prescribed under the brand names Ozempic, for treating Type 2 diabetes, and Wegovy, for weight management, works by mimicking the hormone GLP-1, which is released by the gut after eating. The hormone has several effects in the body, such as stimulating insulin production, slowing gastric emptying and lowering blood sugar.

    It has been hailed for its weight-loss benefits, most conspicuously among celebrities. Oprah Winfrey recently said she uses weight-loss medication and lauded “the fact that there’s a medically approved prescription for managing weight and staying healthier, in my lifetime.” She said it felt “like a gift.”

    But between Jan. 1 and Nov. 30 this year, at least 2,941 Americans reported overdose exposures to semaglutide, according to a recent report from America’s Poison Centers, a national nonprofit representing 55 poison centers in the United States.

    California accounted for about 350 of the reports, or around 12%, according to Raymond Ho, the managing director of the California Poison Control System. Ho said the number roughly corresponds to the proportion of California’s population to the rest of the country.

    The nationwide number of semaglutide overdoses this year is more than double the 1,447 reported in 2022, which was more than double the 607 semaglutide overdoses reported in 2021.

    There were only 364 reported semaglutide overdoses in 2020 and 196 in 2019, less than 10% of the number that occurred so far this year.

    America’s Poison Centers released the data with a disclaimer that the figures likely represent an undercount in the number of cases involving semaglutide, as the center only included those voluntarily reported to poison control centers.

    “It is an alarming trend from a poison center perspective,” Ho said. “We get the usual dosing error calls, and all of a sudden there’s an explosion of people calling much more regularly about this.”

    The use of semaglutide and other GLP-1 imitators has surged in popularity over the last year as a quick and effective way to manage weight loss. More than 4 million prescriptions for semaglutide were issued in the United States in 2020, according to federal data, and usage of the drug has continued to grow since then.

    Dr. Stephen Petrou, an emergency medicine physician and toxicology fellow with California Poison Control, said there were multiple factors contributing to the increase in overdoses.

    “Not only is there rising social popularity” of the drug, Petrou said, “but there’s also wider FDA indications for use.”

    Semaglutide was patented by the Danish pharmaceutical company Novo Nordisk in 2012 and has been available in the United States since the FDA approved it in 2017. The drug was originally released as Ozempic for Type 2 diabetics to manage blood sugar levels. Moderate weight loss was found to be a common side effect of the drug, and the FDA approved a different formulation of semaglutide, called Wegovy, for that purpose in 2021.

    Ho and Petrou said the different formulations of semaglutide could help explain why it has led to so many more overdoses than other drugs of its class. Both are administered via weekly injections, with Wegovy in single-use pens and Ozempic in needles that can vary in dosage. Standard dosages range from 0.25 mg to 2.4 mg for weekly injections, depending on the prescription.

    “Someone who is unable to get Wegovy can resort to using Ozempic instead, because it is the same medication, but they may start to [adjust] their dose” upward, Petrou said. “That’s when they might encounter problems.”

    Ho and Petrou said the vast majority of semaglutide overdose reports are accidental, either due to patients not waiting a week between doses or by misunderstanding dosing instructions. Unlike the GLP-1 hormone, which is rapidly metabolized by the body, semaglutide and similar medications have much longer half-lives, meaning the medication can build up inside the body if not enough time elapses between doses.

    Furthermore, semaglutide can also be taken orally as a daily pill — sold under the name Rybelsus — but overdoses are rarely reported.

    “We’re not seeing cases of mis-administration or toxicity or overdose with that medication,” Petrou said.

    Ho and Petrou explained the signs of semaglutide overdose can resemble those of hypoglycemia, also known as low blood sugar. Symptoms can begin with increased heart rate, sweating, dizziness and irritability. More serious cases can cause confusion, delirium and coma.

    “If they have hypoglycemia, the good majority of them will have to be admitted to the hospital and monitored and watched closely, because of how long these drugs last,” Ho said.

    Ho encourages everyone who is prescribed semaglutide to thoroughly read the medication’s label and follow the dosing instructions listed.

    “We always say this: The dose makes the poison,” Ho said.

    Anyone who needs emergency poison assistance or has other poisoning-related inquiries can call the national Poison Helpline at (800) 222-1222 or visit the Poison Help website.

    [ad_2]

    Jeremy Childs

    Source link